Immediate Impact
33 standout
Citing Papers
Targeted protein degradation: advances in drug discovery and clinical practice
2024 Standout
Therapeutic advances of targeting receptor tyrosine kinases in cancer
2024 Standout
Works of Ziad U. Khan being referenced
I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib
2015
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Ziad U. Khan | 65 | 69 | 64 | 4 | 142 | |
| Sayaka Aoyagi | 144 | 23 | 16 | 4 | 177 | |
| Robert McCroskey | 29 | 84 | 36 | 5 | 138 | |
| Dom McMullan | 53 | 14 | 50 | 5 | 136 | |
| Muhammad A. Rizvi | 33 | 27 | 15 | 6 | 178 | |
| María R. Alonso | 42 | 72 | 8 | 5 | 129 | |
| Christina A. Meadows | 51 | 35 | 13 | 6 | 198 | |
| Martha Perisoglou | 34 | 48 | 9 | 6 | 148 | |
| Celine Chen | 93 | 38 | 28 | 5 | 180 | |
| Vladimir Chernitskiy | 48 | 15 | 50 | 5 | 221 | |
| Matthias Freund | 44 | 27 | 102 | 6 | 193 |
All Works
Login with ORCID to disown or claim papers
Loading papers...